GLMD
HEALTHCAREGalmed Pharmaceuticals Ltd
$0.63+0.04 (+6.41%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GLMD Today?
No stock-specific AI insight has been generated for GLMD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.41$2.34
$0.63
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-2.39
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume299K
Avg Volume (10D)—
Shares Outstanding6.6M
GLMD News
20 articles- Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based TherapeuticsYahoo Finance·May 6, 2026
- Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain CancersYahoo Finance·Apr 14, 2026
- Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, AramcholYahoo Finance·Apr 9, 2026
- Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025Benzinga·Mar 31, 2026
- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationYahoo Finance·Jan 30, 2026
- Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 MeetingYahoo Finance·Dec 8, 2025
- Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASHYahoo Finance·Dec 4, 2025
- Galmed Issues CEO Letter to ShareholdersYahoo Finance·Dec 1, 2025
- Galmed Pharmaceuticals: Q3 Earnings SnapshotYahoo Finance·Nov 26, 2025
- Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 26, 2025
- Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol MeglumineYahoo Finance·Nov 18, 2025
- BC-Most Active StocksYahoo Finance·Nov 17, 2025
- Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitroYahoo Finance·Nov 17, 2025
- Galmed Pharmaceuticals: Q2 Earnings SnapshotYahoo Finance·Aug 28, 2025
- Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Aug 28, 2025
- Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder ValueYahoo Finance·Aug 25, 2025
- Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASHYahoo Finance·May 27, 2025
- Galmed Pharmaceuticals: Q1 Earnings SnapshotYahoo Finance·May 22, 2025
- Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·May 22, 2025
- Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC ModelsYahoo Finance·May 13, 2025
All 20 articles loaded
Price Data
Open$0.57
Previous Close$0.59
Day High$0.59
Day Low$0.55
52 Week High$2.34
52 Week Low$0.41
52-Week Range
$0.41$2.34
$0.63
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-2.39
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume299K
Avg Volume (10D)—
Shares Outstanding6.6M
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment of liver diseases. The company is headquartered in Tel Aviv, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—